IO Biotech, Inc.
NASDAQ:IOBT
0.83 (USD) • At close January 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | IO Biotech, Inc. |
Symbool | IOBT |
Munteenheid | USD |
Prijs | 0.829 |
Beurswaarde | 54,615,274 |
Dividendpercentage | 0% |
52-weken bereik | 0.66 - 1.95 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mai-Britt Zocca Ph.D. |
Website | https://www.iobiotech.com |
An error occurred while fetching data.
Over IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)